Tell us: have you struggled with access to Covid-19 treatment?

2 months ago 3

We would like to hear from people who have experienced any issues or delays in accessing Covid treatments in recent months.

Last year, arrangements for prescribing Covid medications, which include antivirals and neutralising monoclonal antibodies, devolved to the 42 NHS integrated care boards (ICBs) in England. The shift resulted in warnings that eligible patients were struggling to get hold of Covid treatments.

We want to know if the situation has changed.

For example, have you struggled to get access to antivirals? Have you had to chase for your eligibility to be approved?

Share your experience

You can tell us about any issues you have experiences with accessing antivirals for Covid using this form. 

Please share your story if you are 18 or over, anonymously if you wish. For more information please see our terms of service and privacy policy.

Your responses, which can be anonymous, are secure as the form is encrypted and only the Guardian has access to your contributions. We will only use the data you provide us for the purpose of the feature and we will delete any personal data when we no longer require it for this purpose. For true anonymity please use our SecureDrop service instead.

Name

Where do you live?

Tell us a bit about yourself (e.g. age and what you do for a living) Optional

Have you had any issues with accessing treatment for Covid?

Please include as much detail as possible

Do you have any concerns? Optional

If you are happy to, you can upload a photo of yourself here Optional

Please note, the maximum file size is 5.7 MB.

Choose file

Phone number Optional

Your contact details are helpful so we can contact you for more information. They will only be seen by the Guardian.

Email address

Your contact details are helpful so we can contact you for more information. They will only be seen by the Guardian.

You can add more information here Optional

If you include other people's names please ask them first.

By submitting your response, you are agreeing to share your details with us for this feature.

Read Entire Article